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3. EXPLANATIONS AND ABBREVIATIONS
AA = Arachidonic acid
ACS = Acute coronary syndrome
ADP = adenosine-di-phosphate
ADP test HS = ADP + prostaglandin E1; HS = “highly sensitive”
ATP = Adenosine-tri-phosphate
AUC = area under curve
Between–subject variability = inter-individual variability
CABG = Coronary arterial bypass grafting
CAD = Coronary artery disease
CV = Coefficient of variation
GP = Glycoprotein
HPR = High platelet reactivity
LTA = Light transmission aggregometry
MEA = Multiple electrode aggregometry
MI = Myocardial infarction
NO = Nitrogen monoxide
NSTEMI = non-ST-segment elevation myocardial infarction
PCI = percutaneous coronary intervention
PGI2 = prostacyclin
PPP = platelet poor plasma
PRP = platelet rich plasma
Within-subject variability = intra individual variability
STEMI = ST-segment elevation myocardial infarction
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4. SUMMARY
Dual Antiplatelet therapy with aspirin and clopidogrel is a cornerstone in treatment of 
patients with acute coronary syndromes (ACS) and after percutaneous coronary 
intervention (PCI), and aspirin is established as antiplatelet monotherapy in stable
coronary artery disease (CAD). Despite the fact that treatment with aspirin and 
clopidogrel attenuates platelet activity, thrombotic events still occur, and the terms 
aspirin- and clopidogrel “resistance” or “non-responsiveness” - denoting inadequate 
responses to these drugs, have emerged. Before the work on this thesis was initiated,
several studies had demonstrated in vitro on-treatment residual platelet activity, and it 
was hypothesized that patients who respond inadequately to antiplatelet therapy might be 
identified by routine in vitro platelet function testing. However; partly due to lacking 
consensus on definitions, methods and terminology, the prevalence and clinical 
significance of aspirin- and clopidogrel resistance was controversial – and further 
research was needed. In order to evaluate the prevalence of aspirin and clopidogrel 
resistance and to explore and compare two different platelet aggregatory methods we 
performed three aggregometric studies.
In our first study we explored the prevalence of COX-1 related aspirin resistance among 
289 patients with stable CAD who were treated with aspirin. For this purpose we 
performed in vitro testing using arachidonic acid (AA) stimulated light transmission 
aggregometry (LTA) and parallel measurements of plasma thromboxane B2 (TXB2). 
These tests were initially performed on two occasions 2-4 weeks apart and prior to 
coronary angiography. According to LTA aggregation findings, 11 patients showed signs 
of inadequate aspirin response on at least one of the two occasions. However, none of 
these 11 patients showed signs of residual platelet reactivity at a third examination. In 
conclusion, none of our patients presented persistent COX-1 related aspirin resistance.  
In the second study we wanted to explore between- and within-subject variability in 
ADP-stimulated aggregation before and after initiation of clopidogrel therapy. For this 
purpose, we performed ADP-stimulated LTA in the 79 of the 289 patients from our first 
study who underwent PCI and consequently were treated with clopidogrel in addition to
aspirin after the procedure. ADP-stimulated LTA was performed on two occasions before
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- and one after – initiation of clopidogrel therapy. As expected, large between-subject 
variability in aggregation was found both before and during treatment with clopidogrel.
Besides, there were substantial within-subject variations over time before clopidogrel 
treatment and in clopidogrel naïve controls. Although the correlation between pre- and 
post clopidogrel aggregation was significant, reliable predictions of aggregometry 
responses during clopidogrel therapy could not be made based on pre-treatment testing.  
Not only the substantial between-subject variability in ADP-stimulated LTA during 
clopidogrel therapy, but also within-subject variability in aggregation over time before 
clopidogrel, suggested that clinically significant within-subject variations in on-treatment 
aggregation over time might be present. This merited further studies, and in addition we
wanted to compare the relatively slow LTA method with the much faster Multiplate 
Electrode Aggregometry (MEA) method. In our last study we therefore performed 
repeated, parallel ADP-stimulated LTA and MEA aggregation measurements with 3 
different ADP-concentrations in order to explore the agreement between the two 
methods. The patient population consisted of 31 patients who were on dual antiplatelet 
therapy with aspirin and clopidogrel after NSTEMI and were treated with PCI; 
aggregometry was performed on three occasions 6 weeks apart, the first at the time of 
PCI. As aspirin-and clopidogrel treatment aims to inhibit arterial platelet reactivity while
blood sampling acquired for aggregation measurements usually are venous; we also 
wanted to compare LTA and MEA aggregation in venous and arterial blood.
We found that despite substantial between-subject variability, on-treatment aggregation 
was quite stable over time in most patients when assessed by both LTA and MEA, and 
that the agreement between LTA and MEA was good and stable. ADP concentrations had
impact on both MEA and LTA assessments, and should therefore be taken into 
consideration when comparing results based on different ADP concentrations.
We also found that parallel testing in arterial and venous blood showed similar 
aggregation results both for LTA and MEA – suggesting that venous blood sampling is 
sufficient for LTA- and MEA assessments. 
10
5. INTRODUCTION
5.1 THROMBOSIS FORMATION. ASPIRIN AND CLOPIDOGREL 
ENDOTHELIUM AND PLATELETS: Platelets are small anuclear cells produced in the 
bone marrow by the megacaryocytes (1) and have an important role in haemostasis to
detect and repair vascular injuries, as described 130 years ago by G. Bizzozero (2).
Platelets circulate passively as they traverse a vascular tree lined by an intact monolayer 
of endothelial cells. However; when exposed to vessel wall injury they instantly undergo 
the process of 1) adhesion, 2) shape change, 3) secretion and 4) aggregation resulting in 
the formation of a localized haemostatic plug as further outlined below. The interaction 
between platelets and vascular endothelium is essential for maintaining haemostasis (3).
The endothelium consists of a single layer of cells which covers the luminal surface of 
the vessel wall. Under normal conditions the endothelium acts as a physical barrier that 
prevents the blood from coming into contact with sub-endothelial tissues. If it is 
disrupted, blood encounters sub-endothelial tissues containing strong platelet activating 
and platelet binding proteins such as collagen and von Willebrandt factor (vWF). The 
platelets adhere to the disrupted area by their specific vWF receptor (GP Ib-V-IX) and 
collagen receptors (e.g. GP Ia/IIa and GP VI) on the platelet surface (fig. 1) (4-8). In 
addition to passively preventing the blood from coming into contact with the artery wall, 
endothelium is also a source of several vaso - and platelet active substances such as the 
vasodilator Nitric oxide (NO) (3;9), and prostacyclin (PGI2) which acts both as a 
vasodilator and a platelet inhibitor (10;11). When the endothelium is injured, these local 
protective mechanisms are disrupted (12;13). An array of excitatory and inhibitory 
signals bombards the platelet membrane which is equipped with receptors designed to 
recognize a variety of extracellular agonist molecules translating them into complex 
responses by means of second messengers which briefly are outlined below
TXA2 RECEPTOR ACTIVATION AND INTRAPLATELET SIGNALLING: The 
stimulation of platelet membrane receptors at the site of endothelial injury may initiate 
platelet activation through several pathways. Most often this activation occurs via
different cytoplasmic G-proteins which are coupled to the platelet surface receptors 
(14;15). One important example is activation of phospholipase C (PLC), resulting in e.g. 
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mobilization of intracellular calcium stores which in turn triggers activation of different 
intracellular enzymes. One of these enzymes is phospholipase A2 (PLA2), which releases 
arachidonic acid from the platelet membrane. Arachidonic acid is converted – first by 
cyclooxygenase 1 (COX-1) and then by thromboxane A2 (TXA2) synthase – to TXA2 - a
strong platelet agonist (16), (fig. 2). TXA2 diffuses through the platelet membrane and 
induces further platelet activation and recruitment through TXA2 receptors on the 
platelets surface (15) (fig.3). TXA2 is almost instantaneously (T½ approximately 30 
seconds) converted to the more stable TXB2 (16). There are several activation 
mechanisms within the platelet involving a variety of interacting signalling substances 
including different protein kinases and also the adenyl- (AC) and guanyl cyclases (GC) 
important for regulation of the amount of cyclic nucleotides (see below) (15;17).
Activation of platelets also results in platelet shape change by activation of the 
cytoskeleton which is important during thrombus formation (15;17). Also, the 
coagulation system is activated at the site of formation of the haemostatic plug and the 
membrane of activated platelets acts as an important site for coagulation complexes
interacting with platelet activating substances (such as sub-endothelial tissue factor from 
the injured vessel wall), resulting e.g. in production of thrombin which is a strong platelet 
activator (18;19). Interaction between platelets and erythrocytes or leucocytes may also 
enhance aggregation response (20;21) (see below).
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Figure 1: Activated platelets and binding to GP Ib (vWF receptors) at site of endothelial injury and 
fibrinogen binding (GP IIb/IIIa) receptors interlinking the platelets (Frank Brosstad, UiO/OUS).
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Figure 2: Activation of the platelets by COX-1 dependent pathway and COX-1 independent pathways (R. 
Fitzgerald et al., Pharmacology & Therapeutics 130 (2011), 213-225).
ADP RECEPTOR ACTIVATION: Not only mobilization of intracellular calcium stores
but also influx of extracellular calcium is facilitated during platelet activation. The 
resultant increase in intracellular calcium promotes platelet release of stored granules
(15) containing locally acting pro-aggregatory substances such as the platelet agonist 
ADP, adhesive proteins (e.g. fibrinogen), and even more calcium ions (fig. 2 and 3). Two 
different ADP–binding receptors (P2Y1) and (P2Y12) on the platelet surface (14;15),
both coupled to intra-platelet G-proteins (fig.2), are important. Stimulation of the ADP
P2Y1-receptor promotes, by signalling through the Gq-protein, protein kinase activation.
Importantly, stimulation of this receptor also increases the intracellular calcium 
concentration - which in turn contributes to further TXA2 production (14;15) (fig.2 and 
4). Stimulation of the ADP P2Y12 receptor inhibits - through the Gi-protein - cyclic 
AMP (cAMP) formation (14), and further signalling in turn promotes platelet aggregation 
by presentation of the GP IIb/IIIa receptors on the platelet membrane (15;22;23), (fig. 4).
This inhibitory pathway of adenylat cyclase also facilitates decreased phosphorylation of 
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vasodilator-stimulated protein (VASP) -which is cAMP-dependent - and in turn promotes
platelet activation (24), (fig. 2). The presentation of numerous active GP IIb/IIIa
receptors on platelets surfaces is a crucial step in thrombus formation since fibrinogen 
(circulating and released fibrinogen from activated platelet granules) attaches its two 
receptor binding ends to two different platelets via their GP IIb/IIIa receptors -
interlinking the platelets into aggregates (fig 1) (18;22;23).
Figure 3: Activation of the platelets by different pathways and the role of ADP (Bonello et al. JACC 
Vol.56, No 12, sept 14, 2010).
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ATHEROMATOSIS/ATHEROTHROMBOSIS: Inflammation plays an important role in 
atheromatosis and contributes to the development of CAD (20;25-27) in concert with 
lipids. Dyslipidemia is considered to be the initiating cause of atherosclerosis. The intima 
of the arterial vessel wall is infiltrated by LDL-cholesterol particles which become 
oxidized (oxLDL). In response the overlaying endothelium is expressing adhesion 
molecules that make platelets, monocytes and T-cells adhere and migrate into the 
subendothelial space by diapedesis (fig. 5). Chemotactic molecules such as MCP-1, IL-8
and RANTES secreted by these cells stimulate to further recruitment. 
The monocytes entering the subendothelial space become influenced by macrophage-
colony stimulated factor (M-CSF) from endothelial cells to differentiate into lipid 
macrophages with LOX-1 receptors permitting substantial uptake of oxLDL. 
Concomitant phagocytosis of platelets turns them into lipid-laden foam cells (28). These 
cells are prone to apoptosis, releasing their content of oxLDL, chemokines as mentioned 
above and - perhaps most importantly - matrix metalloproteinases (MMPs) (fig 5).
Activated monocytes/macrophages in the plaque area express Tissue Factor that may 
trigger thrombosis after plaque rupture (29). The T-lymphocytes recognize oxLDL as an 
antigen which activate them to release pro-inflammatory cytokines that enhance further 
endothelial and macrophage activation. The cocktail of chemokines also stimulates
Vascular Smooth Muscle Cells (VSMC) to proliferate and migrate into the intima, 
expressing collagen that forms a fibrous cap enclosing the growing plaque (30).
Platelets - apart from their importance in hemostasis - are also potent inflammatory cells 
that play an important role in plaque formation. When activated they display two 
important moieties - CD40 and CD40L - also expressed on macrophages, T-cells, SMCs , 
adventitia cells and endothelial cells- that through CD40-CD40L complex formation 
allows interaction and crosstalk between these cell types (fig. 6). Platelets may enter the 
plaque by leaky micro-vessels in the plaque area or by binding to macrophages and T-
cells that enters the plaque by diapedesis (fig. 5). Platelet interbonding with the other cell 
types in the plaque upregulates the expression of MMPs that proteolyse the fibrous cap 
and make it prone to rupture and subsequent atherothrombosis (31).
ANTIPLATELET DRUGS: The platelets are “inappropriately” activated in 
arteriosclerosis and contribute to the development of CAD - and if the endothelium is 
disrupted after e.g. spontaneous rupture of an atherosclerotic plaque or during 
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percutaneous intervention – the platelets promote formation of an intra-luminal thrombus
and eventually ischemic tissue injury (27;32).
It is evident from our knowledge of normal platelet physiology that platelets can be 
activated in a number of ways, and that several potential targets for pharmacological 
attenuation of platelet activation exist. Accordingly, several drugs that act through 
inhibition of one or more of these mechanisms have been developed in order to prevent 
such “inappropriate” platelet activation. Two of them are aspirin and clopidogrel; the 
theme of this thesis. Aspirin and clopidogrel have been the most common antithrombotic 
drugs in use to prevent thrombotic events in CAD patients (33;34) and their widespread 
use underlines the importance of the platelets in the pathogenesis. 
ASPIRIN: Aspirin substantially reduces the risk of myocardial infarction and death in 
stable coronary disease, and aspirin in combination with clopidogrel prevents ischemic 
events and re-thrombosis in acute coronary syndromes and after PCI (33;34).
One of aspirin’s most important clinical pharmacological effects is to reduce platelet 
production of TXA2 (35). Platelets are mainly exposed to aspirin as blood passes through 
the portal circulation in the liver (32;36). Aspirin mediates its platelet inhibitory effect 
through irreversible acetylation and blockage of the arachidonic acid (AA) binding site
on the COX-1 enzyme – thereby inhibiting formation of TXA2 (32;37). This in turn
attenuates platelet aggregation and vasoconstriction. 
Uncoated (plain) aspirin is absorbed in the stomach, and its platelet inhibitory effect is 
detectable within 30 minutes and reaches its full platelet inhibitory effect– determined by 
a decrease in the serum level of TXB2 – within 60 minutes (36;38). As pointed out 
above, TXA2 is almost instantaneously converted to the inactive, stable TXB2, which 
can be taken as a measure of TXA2 production (16). Peak plasma level of uncoated 
aspirin (corresponding to the salicylate level) is reached within 30 minutes (36) after 
ingestion. Peak plasma level of aspirin after ingestion of enteric coated /controlled release 
aspirin tablets appears later (39;40) and the platelet inhibitory effect - measured as a
decreased serum level of TBX2 – is reached within 6-7 hours (41), to be noted possibly 
dependent on drug design and release (42). Since blockage of platelet COX-1 is 
irreversible, aspirin’s effect lasts throughout the platelet’s lifespan, which is 7-10 days
(32). Previous studies have shown that 30 -50 mg of plain (uncoated) aspirin per day is 
sufficient to inactivate the platelets in healthy subjects and that low-dose aspirin also 
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gives platelet inhibition in CHD patients (43;44), controlled release aspirin also shows 
the same accumulative effect (41).
CLOPIDOGREL: Clopidogrel is absorbed from the intestine as a pro-drug which needs 
to be converted in the liver by the cytochrome P450 enzymes to an active thiol metabolite
and this metabolite exhibits clopidogrel’s platelet inhibitory effect (45). It is assumed that 
on the average only about 15% of the absorbed clopidogrel is converted to the active 
metabolite which reaches maximum serum concentration after approximately 30-60
minutes (46). However, because of variations in clopidogrel’s metabolism, and hence the 
plasma level of the active metabolite the effect of clopidogrel is more difficult to predict
than the effect of aspirin.
The active clopidogrel metabolite causes irreversible inhibition of the ADP P2Y12 
receptor throughout the platelet lifespan (45;46). Blockage of this receptor promotes, by 
signalling through the Gi-protein, inhibited platelet secretion of dense granules and 
ceased inhibition/down-regulation of the adenyl cyclase (AC) (45). These events cause
reduced activation of the fibrinogen binding GP IIb/IIIa receptors on the platelet surface
(15;22-24;47;48). The combined effect is attenuation of platelet aggregation and 
adhesion. ADP P2Y12 receptor occupancy of active clopidogrel metabolite is observed as 
early as 4 hours after ingestion of 75 mg clopidogrel (49). Clopidogrel’s maximal platelet 
inhibition occurs within 4-8 hours after administration of a 600 mg loading dose,
somewhat later after a 300 mg loading dose and within 5-7 days following administration 




5.2 ASPIRIN- AND CLOPIDOGREL “RESISTANCE”
Based on both laboratory studies and clinical studies during the past two decades the 
possibility of inadequate effects of aspirin and clopidogrel in some patients has received
substantial attention (51-53). In principle, variability in antiplatelet responses could be 
related to either pharmacokinetic or pharmacodynamic factors that might affect the 
bioavailability of the drugs and their action on their targets (47;51;54).
Different terms describing inadequate platelet inhibitory effects of aspirin and clopidogrel 
occur in the Literature – among which “non- responsiveness” and “resistance” are the 
most common. Some authors define clinical “resistance” to be present when thrombosis 
occurs despite antiplatelet treatment. However, because platelets are activated through
several mechanisms and aspirin and clopidogrel do not inhibit the entire platelet 
activation cascade, thrombotic events may obviously occur even when the drugs are 
effective. Therefore, a better term describing such “clinical resistance” might be 
“treatment failure” (51). This example shows how discussions of platelet responses to 
aspirin and clopidogrel have been - and still are, complicated by lack of clear definitions 
and terminology. In the context of the present thesis we have decided to use the term 
“resistance” solely when aspirin or clopidogrel might not exhibit their anticipated effects
on their pharmacological targets (55).
Several in vitro methods have been used in order to study pharmacological resistance 
related to antiplatelet drugs. Light transmission aggregometry (LTA) was developed in 
the early 1960-ies and described by Gustav Born in 1962, and this method, also labeled
Born’s aggregation (fig.7), is still considered to be the “gold standard” for studying 
platelet function in vitro (48;55-58). Subsequently, several other methods have been 
developed. These include e.g. measurements of urinary, plasma and serum TXB2, 
impedance aggregometry assays as Multiple electrode aggregometry (MEA),
Thrombelastography (TEG), Phosphorylation of vasodilator-stimulated phosphoprotein 
(VASP), PFA-100 and flow cytometry measurements of various pro-aggregatory proteins 
on the platelet surface (58). In our last study we decided to apply MEA, and to compare 
this method with LTA. 
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In order to study possible pharmacodynamic drug resistance, it is essential to use receptor 
specific methods (55). In case of aspirin this means that methods must be used that can 
identify insufficient blockage of the arachidonic acid (AA) binding site on the COX-1
enzyme. Since AA is the substrate of COX-1, residual platelet activity should be 
measured after adding AA in the test tube (48;55). Similarly, in case of clopidogrel, 
methods should be used that can detect insufficient blockage of the P2Y12 receptor. 
Therefore, the P2Y12 receptor-agonist ADP should be used as agonist to detect residual 
platelet activity after ingestion of clopidogrel (48;55) (fig. 2 and 3). In view of these 
considerations we used AA stimulated LTA in our first study, and ADP stimulated LTA
in the second study. In the third study we used ADP stimulated LTA and ADP stimulated 




At the time when the work on this thesis was initiated, the debate on aspirin resistance 
was characterized by lack of a common understanding concerning methodology, 
definitions and clinical significance. Many studies did not seem to take into consideration 
that platelet activation occurs by multiple pathways that may act independently of 
aspirin’s action. Importantly, the question regarding whether COX-1 might be incapable 
of being blocked by aspirin in some patients was unsettled. In order to resolve this issue 
we specifically wanted to explore possible COX-1 related residual platelet reactivity. For 
this purpose we decided to use the receptor specific LTA, the “gold standard” method for 
studying platelet function in vitro. If patients with COX-1 related aspirin resistance might 
be found that would in our opinion be the “hardest” possible proof of aspirin resistance. 
Our first study was designed in order to elucidate this question.
Study 2
It was evident from previous studies that between-subject variability in clopidogrel 
response was substantial even when using methods specifically aimed at detecting 
blockage of the ADP P2Y12 receptor and that this variability might be of clinical 
importance. However, we discovered that there was a paucity of data regarding the 
impact of the variability of the LTA method itself on these findings, and biological 
within-subject variability in ADP stimulated LTA aggregation over time.
In the second study we decided to explore these possible pitfalls when measuring platelet 
inhibitory effects of clopidogrel by LTA. We also hypothesized that pre-treatment ADP-
stimulated LTA aggregation might predict on-treatment responses to clopidogrel. 
Study 3
As evidence regarding the clinical significance of between-subject variability in response 
to clopidogrel grew, it seemed important to be able to perform in-vitro testing in clinical 
settings in order to eventually adjust the antiplatelet medication. Classical LTA is time -
and labour-consuming. Although several faster tests (like MEA) had been developed, 
expert opinion was that in order to recommend routine platelet function testing more data 
were needed. We therefore wanted to compare the performance of the “fast” MEA vs. the 
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“slow” LTA. Several studies based on single measurements of MEA vs. LTA aggregation 
had been published, but data on long term on-treatment platelet aggregability and long
term agreement between LTA and MEA in several clinical settings were lacking. Both
within subject- and between-subject variability of LTA measurements in patients on 
clopidogrel medication also merited further studies. The primary aims of the third study 
were to explore within - and between-subject variability in on-treatment MEA-and LTA-
aggregation, and to compare repeated, parallel MEA and LTA aggregation over time. We 
also wanted to explore the impact of different agonist concentrations on the aggregation 
assessments. As blood samples acquired for testing usually are venous while the platelets 
play their main role in arterial thrombus formation; we also compared MEA and LTA 




The first paper is based on a population of 289 patients with stable CAD on treatment 
with aspirin who were remitted for coronary angiography. In 270 of the 289 patients AA
stimulated LTA was performed in parallel with plasma TXB2 measurements twice 3
weeks apart while on monotherapy with aspirin. In order to obtain reference values for 
TXB2 we also included a control group of 42 patents without CVD and without 
medication known to interfere with platelet function.
Study 2
The second paper is based on serial measurements of ADP stimulated LTA aggregation 
in the 79 patients from Study 1 who were treated with PCI. The first two measurements 3 
weeks apart were performed before PCI while the patients were on monotherapy with 
aspirin, and the last measurement 3 to 52 weeks after PCI while the patients were on dual 
antiplatelet therapy with aspirin and clopidogrel. A control population consisting of 16 
healthy volunteers without medication known to interfere with platelet function was also 
included in Study 2 in order to provide an estimate of the methodological precision of 
ADP stimulated LTA at different ADP concentrations (10 μM and 5 μM), and to explore 
possible sequential aggregometry fluctuations. 
Study 3
The third paper is based on three sequential, parallel ADP stimulated LTA and MEA 
aggregation measurements 6 weeks apart in 31 patients with NSTEMI who were treated 
with PCI. The patients were on continuous dual antiplatelet therapy with aspirin and 
clopidogrel. The parallel LTA and ADP aggregation measurements were performed using 
three ADP concentrations (10 μM, 6.5 μM and 2 μM). Parallel venous and arterial 
aggregation studies were performed in 10 patients at baseline. 
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8. LABORATORY METHODS 
Light transmission aggregometry (LTA)
As mentioned previously, this method was developed and first described by Gustav Born 
(fig. 7). The method measures the difference between the light transmission through 
platelet rich plasma (PRP) prior to and after addition of a platelet agonist (fig.7). Light 
transmission in platelet poor plasma (PPP) is defined to be 100 % and in platelet rich 
plasma (PRP) to be 0 % before agonists stimulation. The measured values are expressed 
as increase in per cent in light transmission compared to the platelet poor plasma plotted 
against time (definition thresholds for inadequate effect of aspirin or clopidogrel, see 
chapter 10.1). This method is time- (approximately 2 hours) and labour- consuming and 
is only performed in dedicated laboratories and university hospitals.
Multiple electrode aggregometry (MEA)
The MEA method is based on the activated platelet’s ability - after stimulation by an 
agonist; e.g. AA or ADP - to adhere to and to form aggregates on electrode surfaces (i.e. 
metal sensor wires) in whole blood. This testing is performed in anticoagulated whole 
blood. MEA detects the increase in the electrical impedance resulting from adherence of 
activated platelets and – aggregates between the two electrodes. The impedance increases 
proportionally to the number of adhering platelets. The increase in impedance is 
transformed to “aggregation units” (AU or U) and is plotted against time (definition 
thresholds for inadequate effect of aspirin or clopidogrel, see chapter 10.1). MEA is 
substantially less time-consuming (approximately 20 minutes) than LTA.
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Fig. 7: Principles of Born’s aggregometry, first described in 1962 (Prof. Frank Brosstad UiO/OUS)
Plasma Thromboxane B2
Aspirin mediates its platelet inhibitory effect through irreversible acetylation of COX-1
which inhibits formation of the strong platelet agonist Thromboxane A2 (TXA2) from 
arachidonic acid (AA). As mentioned previously, TXA2 is almost instantaneously
converted to the inactive and stable TXB2 - which can be taken as a measure of TXA2 
production. An ACE competitive enzyme immunoassay kit (TXB2 EIA kit, Cayman 
Chemical Company) was applied for measurements of plasma TXB2. Measurements of 
plasma TXB2 were performed in batches weeks to several months after sampling. 
Sequential analyses of control samples indicated that there was no drift in TXB2 as a 




Based on two measurements of AA-stimulated LTA aggregation 3 weeks apart in 270 of 
the 289 patients (fig. 8), 11 (4.1%) had aggregation 20% on at least one occasion. These 
11 patients were tested a third time, with aggregation <20% in all eleven before 
witnessed ingestion of 300 mg of aspirin. Thus, all patients demonstrated an ability to 
respond normally to aspirin (fig.9).
Average plasma TXB2 level was, as expected, considerably higher in the control group
(mean 173 pg/mL, range 8-788 pg/mL) than in patients who were taking aspirin (mean 19
pg/mL, range 1-181 pg/mL) (fig.10). However, the overlap was substantial and taking 45
pg/mL as the TXB2 cut-off level, sensitivity and specificity for detecting patients taking 
aspirin was 90% and 89%, respectively. 
Although their aggregometry response was the same, plasma TXB2 was significantly 
higher in patients taking aspirin 75 mg daily compared to patients taking 160 mg (fig.10).
In the eleven patients who were tested a third time, plasma TXB2 was significantly 
higher before than after witnessed ingestion of aspirin – despite the fact that their 
aggregometry responses were the same (fig.9).
We conclude that pharmacodynamic aspirin resistance must be rare. However, our data 
suggest that some patients may – at least temporarily – require higher and /or more 
frequent aspirin dosage to achieve the desired antiplatelet effect.
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Figure 8: Box plot of arachidonic stimulated platelet aggregation in the first study; exam 1 (289 patients) 
and exam 2 (270 patients) (paper 1).
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Figure 9: Arachidonic acid stimulated platelet aggregation (panel A) and plasma thromboxane B2 (TXB2) 
in possible aspirin non-responders (panel B) (paper 1)
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Figure 10: Box plots of plasma Thromboxane B2 (pg/mL). 
Panel A: Aspirin (ASA) group (left side; 289 patients on a daily dose of 75 or 160 mg enteric coated 
aspirin) and in the control group (right side; 42 patients not taking aspirin). 
Panels B (Exam 1) and C (Exam 2): Patients taking 75 mg (left) and 160 mg (right). All plots show the 
median value and the 10th, 25th, 75th and 90th percentile. Observations below the 10th percentile and 
above the 90th percentile are represented as dots (paper 1). 
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Paper 2
ADP-stimulated  LTA aggregation was measured in the 79 patients who were treated 
with PCI on two occasions 2-4 weeks apart (Exams 1 and 2) while still on mono 
antiplatelet therapy with aspirin, and a third time 3-52 weeks after PCI while on dual 
antiplatelet therapy with both aspirin and clopidogrel (Exam 3). Between-subject 
variability was substantial (range 17-77%, SD 11.0% during Exam 1), and within-subject 
changes between Exams 1 and 2 were significant (range -27% to +36%, SD 14.6%,
p<0.05).  Between-subject variability was even larger during Exam 3 (while the patients 
were on dual treatment with clopidogrel and aspirin) than during Exams 1 and 2 (p<0.01). 
The correlation between aggregations at Exams 2 and 3 was significant, but moderate 
(RR 0.40). AA-stimulated aggregation was the same before and after initiation of 
clopidogrel therapy. 
In the aspirin and clopidogrel QDʀYH control population (not on antiplatelet therapy) 
aggregation was stronger and between-subject variability smaller when using ADP 10 
μM than when using ADP 5 μM (fig.11). Measurement error was about 6% at both ADP 
concentrations. 
The main conclusions in paper 2 are that since between-subject variability and within-
subject variability over time was substantial, prediction of aggregometry responses to 
clopidogrel based on pre-treatment tests is unreliable. We also conclude that comparisons 
of aggregometry responses should be performed with caution especially if ADP 
concentrations are not standardized. 
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Figure 11: ADP-stimulated platelet aggregation in 16 healthy subjects using 5 μM ADP (panel A) and 10 
μM ADP (panel B). In each subject, blood from the same sample was analysed 4 times at each 
concentration of ADP. Data from the first of two examinations 3 weeks apart, see text (Paper 2)
Paper 3
We found only minor changes in mean LTA- and MEA aggregation over 12 weeks at any 
ADP concentration. Higher ADP concentrations were associated with stronger LTA and 
MEA aggregation and higher between-subject variability (fig.12). Within-subject 
variability in LTA aggregation throughout the study was 7.8%, 8.2% and 5.4% at ADP 
concentrations 10 μM, 6.5 μM and 2 μM, and corresponding variability in MEA 
aggregation was 8.8 U, 9.3 U and 7.9 U. 
When using the suggested consensus value of 47 U MEA aggregation as cut-off for HPR
in MEA and 47% as cut-off value for HPR according to LTA and using the HPR 
classification according to LTA as reference, 87.1% of the MEA observations gave 
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correct HPR classification. Only 6.5% of the MEA vs. LTA observations indicated 
absence of HPR according to MEA in presence of HPR according to LTA (fig. 13).
Both LTA and MEA showed the same aggregation values in venous and arterial blood.
We conclude that within-subject variability over 12 weeks in both MEA and LTA 
aggregation in NSTEMI-patients on clopidogrel and aspirin medication was moderate,
and that the agreement between LTA and MEA was good and stable over time in most 
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Figure 12: MEA and LTA with 3 different ADP coQFHQWUDWLRQVDQGȝ0$'3DVVHVVHGZHHNV
apart in 31 patients with NSTEMI (paper 3).
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Figure 13. Line chart showing the agreement between MEA and LTA aggregation during
phase 1-3. 
Panel A: Group with HPR according to MEA (MEA aggregation > 47 U)




10.1 ANTIPLATELET EFFECTS OF ASPIRIN AND 
CLOPIDOGREL. IN VITRO AGGREGATION AND AA 
STIMULATED LTA, ADP STIMULATED LTA AND MEA
Choice of methods 
Aspirin and clopidogrel do not inhibit all pathways of platelet activation. Thus; platelet 
activation and thrombus formation may still occur - even in the presence of adequate 
pharmacological effect of these two agents.
Several in vitro methods have been developed in order to determine the effects of 
antithrombotic medication such as aspirin and clopidogrel (58). These methods are based 
on assessments of different aspects of the thrombotic cascade and may differ 
substantially. Residual platelet reactivity may be tested unspecifically by exposing 
platelets e.g. to collagen, which may induce aggregation despite full effects of the drugs.
As a consequence, results from different studies based on different methods are not 
directly comparable. A crucial aspect in this context is to what extent the methods
actually assess the anticipated effect of the specific drug – and consequently their ability 
to detect a failure to achieve the desired pharmacological response. In our studies we 
have focused on aspirin and clopidogrel. Therefore, it was essential to use methods that 
might reveal to what extent the AA binding site on COX-1 was inhibited by aspirin and 
to what extent the ADP P2Y12 receptor was inhibited by clopidogrel’s thiol metabolite 
(47;48;55) (fig. 2 and 3).
In our studies we decided to use AA- and ADP stimulated LTA in order to detect residual 
aggregation during aspirin- and clopidogrel medication, respectively, since – as 
mentioned previously, this method is still considered to be the “gold standard” among in 
vitro platelet function tests and the LTA is assumed to be less affected by extra platelet 
COX-1 pathways of platelet activation than several other tests (59). MEA measures 
aggregation in whole blood, and is one of several alternative methods developed for 
simpler and less time consuming assessment of platelet function. Previous studies have
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indicated that the correlation between MEA and LTA is fairly good. The main 
differences between these two methods are that LTA takes place in platelet rich plasma 
while MEA is performed in whole blood which may be considered a more “physiologic 
environment”, and that LTA assesses platelet aggregates in a liquid phase while MEA 
measures platelet adherence to surfaces.
TXB2 and antiplatelet effects of aspirin
Aspirin irreversibly inhibits both COX-1 and COX-2 (37), but at low aspirin doses this 
inhibition almost exclusively relates to platelet COX-1 (36;40). Platelets contain 
considerably more COX-1 than COX-2 (60). Blockage of platelet COX-1 by aspirin is 
irreversible, and since platelets are unable to regenerate COX-1, inhibition of TXA2 
production lasts throughout the 7-10 days platelet lifespan (32).
After being synthesized, TXA2 is quickly converted to the inactive and stable TXB2
which can be taken as a measure of TXA2 production (16;43). As expected, we found 
that plasma TXB2 was much lower in patients taking aspirin compared to controls.
Interestingly - but not surprisingly, and despite the fact that AA stimulated LTA 
aggregation was similar, reduction in plasma TXB2 was dependent on aspirin dosage
(43). Accordingly, patients taking 160 mg aspirin had lower TXB2 than patients taking 
75 mg aspirin. Moreover, plasma TXB2 was further lowered after ingestion of 300 mg 
aspirin among the 11 patients with possible aspirin resistance. This TXB2 may have 
originated from platelets or extra-platelet sources. It may be hypothesized that an 
elevated TXB2 level can indicate a lowered threshold for developing an insufficient
platelet inhibitory effect of aspirin. If this is the case, some patients may – at least 
temporarily – require a higher or more frequent aspirin dosage. 
In most papers where platelet inhibitory effects have been studied by assessment of 
TXB2 production, serum TXB2 – and not plasma TXB2 – has been measured. Therefore,
although similar, our data are not directly comparable to these studies. Despite the fact 
that mean plasma TXB2 was almost 10 times higher in the control subjects (without 
aspirin medication) than in patients taking aspirin, there was a substantial between-
subject variability which caused a reduction in diagnostic power. 
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Antiplatelet effect of clopidogrel
It is clopidogrel’s thiol metabolite that conveys the drug’s action by selective inhibition 
of the platelet P2Y12 receptor(45;46). Human platelets express two ADP receptor 
subgroups on the platelet plasma membrane that are coupled with G-proteins; the P2Y1
receptor and the P2Y12 receptor (15;61). Stimulation of the ADP P2Y1 receptor 
promotes activating of protein kinase C (PKC) and platelet shape change, and also signals
- through the Gq-protein - calcium mobilization (15;61). Stimulation of the ADP P2Y12 
receptor induces - through the Gi protein - secretion of platelet granules and also causes 
amplification of platelet aggregation by activation of fibrinogen-binding GP IIb/IIIa 
receptors on the platelet surface (15; 22-24;61). The latter platelet activating mechanisms 
are inhibited by the binding of clopidogrel’s thiol metabolite to the platelet ADP P2Y12 
receptor.
Interpretations of AA- and ADP stimulated LTA measurements
AA stimulated LTA is considered to be a robust method for assessing COX-1 inhibition. 
During interpretation of the LTA aggregation curve both maximal aggregation and late 
aggregation (i.e. after 6 minutes) have been used. Findings based on these definitions are 
strongly correlated (62), and in our studies we measured maximal aggregation – which is 
the most common approach (47). Stimulation with AA showed little or no residual 
platelet activity among our patients which is in accordance with previous studies (55;63).
The AA concentration that was used in our study is the recommended concentration and 
by far the most common, and LTA aggregation >20% (after AA-stimulation) is usually 
considered as indication of an insufficient effect of aspirin (48).
Non-responsiveness to clopidogrel has been defined differently in different studies. ADP
stimulated LTA aggregation >70% has been used frequently (64-69). Other definitions 
that have been applied are ADP stimulated LTA aggregation >50%, the upper quintile of 
LTA (or MEA) aggregation in the respective patient populations, percent decrease in post 
treatment aggregation compared to baseline (usuDOO\ǻ, or just the absolute 
difference between baseline and post treatment aggregation values (47). However, the 
agreement between these definitions may be poor (47;59;62). Interestingly, given the
>70% ADP stimulated LTA aggregation as cut-off for insufficient clopidogrel response
none of the patients in our studies (paper 2 and paper 3) had clopidogrel resistance. This 
may indicate that drug compliance in our studies was good.
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Clopidogrel response assessed by ADP stimulated LTA and MEA aggregation implies
interpretation uncertainty since only the ADP P2Y12 receptors - and not the ADP P2Y1
receptors – are inhibited. To what extent activation of ADP P2Y1 receptors influences 
interpretation of – and comparisons between - LTA and MEA aggregation measurements 
is an unsettled issue. 
Between-subject differences in ADP-stimulated LTA were substantial and significant 
among both patients and controls (paper 2) and larger than the measurement error among
controls at both ADP concentrations. Under the assumption that the measurement error 
was similar in the both groups we concluded that the observed between-subject 
differences reflected true biological variations in the response to clopidogrel.
The concentration of the agonists is important both during MEA and LTA, as high 
concentrations promote stronger aggregation. This has been clearly demonstrated both in 
RXUVWXGLHVDPRQJFORSLGRJUHOQDʀYHKHDOWK\FRQWUROV and in on-treatment CAD patients,
as well as in other studies (47;70;71). The ADP concentrations that are usually applied in 
laboratories are far higher than ADP concentrations encountered physiologically, and
such high concentrations usually induce a pronounced aggregation (22;57). ADP 
concentrations >10 μM (e.g. 20 μM which is commonly applied (47)) are probably not 
advantageous methodologically (71). Thus, in our last study, within-subject variability in 
both MEA and LTA on-treatment aggregation was lowest at the lowest ADP 
concentration (2 μM) but did not differ significantly between the two highest ADP 
concentrations (6.5 μM and 10 μM).
Interestingly, although between-subject variability in on-treatment LTA and MEA
aggregation was lowest at the lowest ADP concentration (2 μM compared to 6.5 and 10
μM, paper 3), between-subject variability was highest at the lowest ADP concentration 
among clopidogrel QDʀYHcontrol subjects (5 μM compared to 10 μM, paper 2). These 
findings are in concordance with previous studies (71). One likely explanation is that 
patients on clopidogrel treatment present various blockage of the ADP receptors, which 
causes a substantial dispersion of the aggregation values. On the other hand, individuals 
who do not use clopidogrel, present stronger aggregation responses in general, this
probably causes the clustering of aggregation values up towards the maximum 100% 
value. One additional aspect to consider regarding these and other ADP stimulated 
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aggregation data is the possibility of an inherent variability in platelet ADP response -
also with respect to the non-inhibited P2Y1 receptor (14) - which may, at least partly, be 
independent of clopidogrel metabolism and that this difference is unmasked by the higher 
concentration of ADP. Genetic differences in the ADP 2PY12-receptor may possibly
explain some of these effects (72) but not necessarily all (70;73).
Considerations about ADP-stimulated MEA 
In our last study we used 3 different ADP concentrations in LTA and MEA - including 
the concentration recommended by the manufacturer (6.5 μM) for MEA. We did not add 
Prostaglandin E1 (PGE1) (=ADPtest HS) in MEA as the manufacturer recommends for 
making the method more sensitive to clopidogrel since this may also lower the specificity 
of the test - the latter also according to the manufacturer (Compendium by Andreas 
Calatziz, Ralph Loreth and Michael Spannagl; “Multiplate platelet function analysis-
application and interpretation”). However, ADPtest HS  and the “plain” ADP stimulated 
MEA are strongly correlated and the latter also correlates well with LTA (74). Moreover,
the agreement between the “plain” ADP stimulated MEA and LTA is acceptable even
when using the same ADP concentration (10 μM) in both assays (68;69;75). 10 μM ADP 
has been recommended as the standard concentration when assessing clopidogrel’s 
antiplatelet effect using LTA (71). In order to keep anticipated specificity as high as 
possible according to the manufacturer we used only ADP as agonist for assessment of 
clopidogrel effect by the MEA assay in our study. We applied the suggested consensus 
value >47 U (47) as the cut-off definition threshold for inadequate clopidogrel response.
10.2 ASPIRIN RESISTANCE OR NON-RESPONSIVENESS 
As mentioned previously, aspirin resistance has been intensely debated. However, there 
seems to be increasing agreement among authors that, when using assays that reflect 
inhibition of the target COX-1 enzyme as in our study the platelet inhibitory effect of 
aspirin is predictable and strong in the large majority of patients - with an “all or none”
response. Furthermore it is assumed- as also suggested in our study- that a lacking in 
vitro effect of aspirin most often is associated with non-adherence to medication and 
methodical aspects; and is not a matter of drug resistance (55;63). Thus, our findings are 
in agreement with other studies (55;62;63;76).
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Using methods measuring general platelet reactivity may show considerable aggregation 
despite aspirin treatment, which may mirror a high pro-aggregatory status due to acute 
phase or a general heightened pro-thrombotic situation (63). Treatment failure may occur 
with aspirin as with other medication, emphasizing that the pathways of platelet 
activation are complex. Although platelet COX-1 enzymes are inhibited by aspirin in 
vitro, extra platelet sources of TXA2 may still cause activation of platelets, aggregation 
and thrombosis. Leucocytes, especially the macrophages, erythrocytes and endothelial
cells contribute to TXA2 production both through the COX-1 pathway and by increased 
expression of COX-2 during inflammation - including atherosclerosis (54;60;63). These 
cells, which also express COX-2, may – unlike platelets – be capable of COX-1
regeneration and TXA2 production during treatment with aspirin.
Inflammatory states, as e.g. seen in diabetes mellitus, in the metabolic syndrome, in
obesity and in acute coronary syndromes, may contribute to a pro-thrombotic situation 
and a weaker antiplatelet effect of aspirin (63;77). Obesity or high body weight may 
present lower enteric coated aspirin responsiveness as determined by serum TXB2 and 
possibly also by AA stimulated LTA (42;78;79). Among the 11 possible aspirin non-
responders patients in our first study the CRP level and proportion of diabetics was 
similar to the rest of the study population. However, as mentioned previously, they had 
significantly higher TXB2 levels. As shown in our study (paper 1), higher doses of 
aspirin inhibit overall production of TXA2 to a larger extent than lower doses. It is 
conceivable that this is caused by a more pronounced inhibition of extra platelet sources 
of COX-1 mediated TXA2, and also to a certain extent by stronger inhibition of COX-2
(60;63). Several other factors in addition to TXA2 and ADP; - i.e. collagen, thrombin, 
inflammatory substances, leucocytes, erythrocytes and shear forces contribute to platelet 
activation despite adequate platelet COX-1 inhibition by aspirin, and possibly contribute 
to the high degree of “aspirin resistance” shown in some studies (47;54;60;63).
As already pointed out, there is still a possibility that insufficient COX-1 inhibition
during treatment with aspirin may occur, at least temporarily. During the first study a
total of 11 patients showed, for no identifiable reasons, an insufficient response to 
aspirin; two patients even on two occasions. Principally, as long as drug-adherence to 
medication is satisfactory; treatment failure of aspirin may be pharmacokinetic (failure to 
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achieve adequate drug level) or pharmacodynamic (insufficient inhibition of platelet 
COX-1 despite adequate aspirin absorption):
PHARMACOKINETIC
x Insufficient bioavailability may occur due to insufficient dosing regimes. Aspirin 
is de-acetylated at various sites including the relatively alkaline milieu in the 
small intestine. The low pH in the ventricle protects against de-acetylation and 
favors absorption of plain aspirin. Bioavailability of plain aspirin is approximately 
50% (36). Enteric coated aspirin is released in the upper intestine where the pH is 
higher and de-acetylation may occur and bioavailability of aspirin could be 
lowered. Thus, enteric coated aspirin may, especially in the presence of high body 
weight or CAD, cause insufficient bioavailability as determined by attenuated 
reduction in serum TXB2 and also AA-induced LTA (42;54;78-80). Differences 
in dissolution in the intestine between different enteric preparations may also exist 
and restrict bioavailability (42).
x New platelets are generated at a rate of approximately 10% daily (32). Increased 
platelet turnover and hence platelet count makes the short exposure time of 
platelets to aspirin insufficient to achieve inhibition of a sufficient proportion of 
the platelet COX-1 (81). The immature platelets may contain COX-1 and also
COX-2 enzymes which are unexposed to aspirin and thus contribute to TXA2 
production (54;60) which may be considered as pharmacokinetic insufficiency.
PHARMAKODYNAMIC
x Competitive but reversible COX-1 binding and inhibition by NSAID’s, e.g.
indomethacin, prevents acetylation of COX-1 (54;82). When indomethacin is 
reversibly attached to the AA binding site, it remains un-acetylated since 
acetylation mostly takes place over a rather short time in the portal circulation due 
to the short half life of aspirin in serum. 
x As far as we know in-vitro aspirin resistance with respect to insufficient 
inhibition of the COX-1 pathway must only to a very limited extent be influenced 
by genetic factors (63;72;83).
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UNSATISFACTORY DRUG ADHERENCE
Non-compliance to medication is an important issue. To overcome non-compliance in 
clinical trials, witnessed ingestion is preferable, but is difficult to implement. We had no 
interviews before the second blood test in Study 1, and only contact by telephone a few 
days before blood sampling in order to remind the patients of drug adherence. Neither did 
our study protocol advocate pill counting, which would have been scientifically 
advantageous. Despite our strong efforts to ensure drug adherence throughout all of our 
studies, we believe that the 11 patients in our first study were not fully compliant. Our 
observations are in agreement with other studies (47;55;63;84). Non-adherence to 
medication represents a continuous challenge in assessments of drug response in a 
clinical setting. In our final study only 31 patients participated in a rather short period of 
follow up (12 weeks), including 2 telephone calls and interviews during blood sampling 
which probably enforced drug-adherence
10.3 CLOPIDOGREL RESISTANCE OR NON-
RESPONSIVENESS
Since arterial thrombus formation is a multifactorial process, thrombosis may occur even 
when clopidogrel works effectively. As in the case of aspirin, non-compliance, under-
dosing, obesity, drug-drug interactions, accelerated platelet turnover and increased 
inflammatory activity are possible causes (47;85). Still, many pharmacodynamic and 
pharmacokinetic aspects of clopidogrel are different compared to aspirin, and aggregation 
measurements of clopidogrel’s effect show large between-subject variability in contrast 
to aspirin which shows an almost “all or none” response.
Reduced bioavailability of active clopidogrel metabolite resulting in the substantial 
variability in clopidogrel response according to aggregation measurements is first of all 
believed to rely on impaired absorption from intestine and on the clopidogrel 
metabolizing capacity by the liver P450 enzymes (47;72). Both these factors are highly 
influenced by genetic factors (47;72;86;87). Clopidogrel metabolism in the hepatic 
cytochrome P450 system involves several isoenzymes among which especially 
polymorphisms of the CYP2C19 gene seems to be the most prominent genetic 
44
determinant of clopidogrel response (72;86;87). Another important genetic determinant 
of clopidogrel’s bioavailability is the ABCB1 gene which encodes for the efflux pump P-
glycoprotein important for intestinal absorption of clopidogrel and is also of clinical 
importance (72;86;87).
In a study by Sibbing et al. (88), the plasma concentration of the active thiol metabolite
correlated with 5 μM ADP stimulated LTA measurements, and was significantly lower 
in the few patients with stent thrombosis – underlining the importance of proper 
clopidogrel metabolism. In a study by Bouman et al. (89) plasma concentrations of active 
metabolite correlated with in vitro aggregation measurements by the VASP-assay, the 
Verify-Now P2Y12-assay and 20 μM – but not 5 μM - ADP stimulated LTA. However,
the actual amount of P2Y12 receptor occupancy by the clopidogrel metabolite is also 
important, since the amount of metabolite in plasma not necessarily predicts the extent of 
binding and inhibition of ADP P2Y12 receptors (49;70) measured by various methods. In 
the studies by Sollier et al. it was shown that the amount of clopidogrel metabolite
occupancy of the P2Y12 receptor correlated with LTA aggregation. Other contributing 
factors to impaired clopidogrel response might hypothetically be other genetic variations 
of the platelet ADP receptors, but such factors are thought to be of minor clinical 
importance (72). Interaction with other medication, especially drugs metabolized by 
hepatic cytochrome P450, may either enforce or weaken clopidogrel efficiency.
Rifampicin and St. Johns wort are know to stimulate metabolism by CYP 3A4 and 
thereby enhance the platelet inhibitory effect of clopidogrel, while erythromycin,
ketoconazole, proton pump inhibitors (e.g. omeprazole and esomeprazole), statins (i.e. 
atorvastatin) and calcium canal blockers may attenuate the effect of clopidogrel. The 
clinical significance of these interactions is, however, unclear (90-93).
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10.4 LTA VS MEA; METHODOLOGICAL 
CONSIDERATIONS
Methodological differences between LTA and MEA
As suggested by their names, both LTA and MEA (paper 3) are aggregometric methods.
However, they are based on different principles (58), and it is by no means obvious that a 
good agreement between the two methods would be found:
1. Change in light transmittance detected by a photometer (LTA) is caused by changes in 
platelet shape and adherence causing formation of aggregates in a liquid phase. During 
MEA the change in electrical impedance between two electrodes caused by platelet 
adherence and aggregation on the electrode surfaces is measured. The impedance
increases proportionally to the quantity of adhering platelets. Adherence to surfaces is an 
important aspect of platelet aggregation in vivo, and for this reason it may be claimed that 
MEA gives a better assessment of residual platelet reactivity. At the bottom line,
however, both methods assess activation of platelets fibrinogen binding GPIIb/IIIa 
receptors which facilitate platelet adherence and a prerequisite for the formation of 
platelet aggregates. 
2. LTA is performed in an artificial milieu and includes centrifugation to obtain PRP, and 
this process may alter platelet function. MEA is performed in whole blood and the 
cellular environment remains unchanged - including erythrocytes and leucocytes. This
milieu is considered to be more physiological compared to the PRP. 
3. During blood sampling for in vitro assessments of both LTA and MEA aggregation,
interference with intracellular platelet calcium ion concentrations is inevitable. Calcium 
is, as previously mentioned, involved in several aspects of platelet function and 
activation. Citrate is the most commonly used anticoagulant but lowers the calcium ion 
concentration and may cause reduced fibrinogen binding to the GP IIb/IIIa receptors and 
thus less aggregation (94) . Although some authors do not find differences between MEA 
assessments based on hirudin and citrate anticoagulated specimens (69), our MEA 
assessments were performed in whole blood using hirudin anticoagulation as 
recommended by the manufacturer. Hirudin, a direct thrombin inhibitor, does not affect 
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the free calcium concentration in the sample. LTA was performed on blood collected in 
Vacutainer with sodium citrate. 
4. LTA is more time- and labour consuming than MEA, and the analysis is more 
complicated to perform than MEA - including more procedural steps that may increase
the risk of operator dependent errors. Importantly, during our studies both LTA and MEA 
were performed by experienced laboratory technicians, and risk of errors associated with 
both procedures was therefore, negligible. 
5. LTA aggregation has fixed lower and upper limits (0% and 100%), while MEA has no 
fixed upper limit. Therefore, the statistical relationship between the two methods is non-
linear. Consequently, application of conventional methods for exploring between-test 
agreement (like Bland-Altman analyses) is not straightforward. 
10.5 WITHIN- AND BETWEEN SUBJECT VARIATION 
OVER TIME IN ADP-STIMULATED LTA AND MEA
Pre- and on-treatment ADP stimulated MEA and LTA aggregation
Our second study showed that the correlation between LTA aggregation before and after 
initiation of clopidogrel therapy was statistically significant, but weak. These findings are
in agreement with other studies. Thus, pre-treatment LTA aggregation should not be used 
in order to predict a patient’s response to treatment with clopidogrel (47).
MEA vs. LTA and timing of on-treatment aggregation measurements
Within subject variability over time in both MEA and LTA aggregation was moderate
and similar at all ADP concentrations (variation coefficients 17% and 18%, respectively, 
using 10 μM ADP). These observations are similar to previous findings over short
periods of time in stable CAD patients (95). In our study of unstable CAD patients (paper 
3), time between clopidogrel loading dose and the first aggregation measurements was 1 
to 4 days, and as also shown in previous studies, the response to clopidogrel as 
determined by LTA seemed to improve somewhat over time – between exam 1 and 
exam 2 - but was not statistically significant. The overall agreement between MEA and 
47
LTA during the 12 weeks observation period was good since the great majority (87.1%) 
of the MEA observations gave “correct” high platelet reactivity (HPR) classification 
according to LTA. 
Accordingly, our data suggest that assessment of antiplatelet reactivity only a few days 
after initiation of therapy during NSTEMI may not be optimal. On the other hand, it may 
be appropriate from a practical point of view, and altogether our findings suggest that on-
treatment measurements of LTA or MEA aggregation performed at one point in time –
even a few days after initiation of clopidogrel therapy, may give a reasonably 
representative picture of the long term antiplatelet effect of clopidogrel. However, the 
measurements should be judged with caution. 
ADP stimulated MEA and LTA and choice of ADP concentrations 
As expected, higher ADP concentrations were associated with stronger aggregation
(47;70;71). It is noteworthy that between-subject variability in on-treatment LTA and 
MEA aggregation increased with higher ADP-concentration (2 μM ADP vs. 10 μM
ADP). Thus; comparisons of aggregation measurements are of limited value if agonist 
concentrations differ. However, the difference between LTA aggregations at 6.5 μM vs. 
10 μM ADP was small, and there was no significant difference in 10 μM ADP stimulated
MEA vs. 6.5 μM ADP stimulated MEA aggregation. Importantly, between-subject
variability in ADP 6.5 μM vs. 10 μM MEA and LTA aggregation was similar.
Consequently; if between-subject variability in MEA and LTA aggregation is an 
indicator of differences in perceived responses to clopidogrel, the 6.5 μM and 10 μM
ADP concentrations may be interchangeable. 6.5 μM ADP is recommended as the 
standard concentration in MEA, while 10 μM ADP has been recommended as the 
standard concentration in LTA in previous publications (71).
MEA and LTA aggregation in arterial and venous blood
We found that MEA and LTA aggregation in arterial and venous blood was similar. 
Some theoretical considerations suggest that aggregation in arterial and venous blood 
samples might be different (96): Different sampling conditions (higher pressure, shorter 
exposure to foreign surfaces during arterial sampling), different concentrations of platelet 
active substances in arterial compared to venous blood and assumed higher prostacyclin 
and nitric oxide production in arterial endothelium may theoretically affect the 
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aggregation results. To our surprise, only one very recent previous study had compared 
MEA aggregation in arterial and venous blood (96). Our data confirmed the findings 
from that study. In our opinion these observations are important, since they indicate that 
venous blood sampling – which is the most common method, reflects platelet reactivity in 
arterial blood; the target for antiplatelet therapy in CAD.
10.6 FUTURE ASPECTS OF HIGH PLATELET 
REACTIVITY ASSESSMENTS
Assessments of residual platelet reactivity and clinical use
Increased platelet reactivity assessed by both LTA and MEA (and other methods) is 
associated with increased risk of thrombotic events in patients treated with aspirin and 
clopidogrel (64;66;97-101). Several studies have attempted to define threshold values for 
in vitro platelet reactivity in patients treated with clopidogrel. However, tailored 
antiplatelet therapy (e.g. increased dosage) for patients with high in vitro platelet 
reactivity according to such thresholds does not necessarily reduce the risk of thrombotic 
events (102). Thus- although e.g. a doubled maintenance dosage of clopidogrel is 
associated with reduced ADP stimulated LTA aggregation and particularly in patients 
with high platelet reactivity (103)- no studies have so far shown that routine assessments 
and dosage adjustments are associated with improved outcome.
In vitro assessments of platelet inhibition are test-specific, and different methods do not 
necessarily identify the same individuals with low drug responses (62;65;67;69;74-76).
Interestingly, in our last study (paper 3) almost 90% of the LTA vs. MEA aggregation 
measurements gave the same high vs. low on-treatment platelet reactivity classification,
indicating that the agreement between LTA and MEA was fairly good. However, at the 
bottom line the clinical significance of all in vitro methods must be evaluated in clinical 
studies that are aimed at exploring associations between high on-treatment residual 
platelet reactivity and clinical endpoints. Furthermore, “tailored” therapies guided by in 
vitro assessments of platelet reactivity must obviously be evaluated in clinical trials and 
tested for superiority compared to standard therapies. 
49
Thus, in lack of consensus regarding choice of methods, lack of agreement on cut-off 
values indicating increased thrombotic risk and lack data demonstrating that altered 
aspirin and clopidogrel dosing improves outcome, the current expert opinion is that 
introduction of routine in vitro platelet function testing in clinical practice is premature
(47;55).
New treatment guidelines for ADP P2Y12 antagonists in CAD
Over the last years the new oral ADP antagonists prasugrel (TRITON TIMI-38) and 
ticagrelor (PLATO) have shown promising results and are considered to be more reliable 
inhibitors of the ADP P2Y12 receptors than clopidogrel and have recently been 
implemented in treatment guidelines for ACS (33;34).
Prasugrel is a thienopyridine pro-drug which – like clopidogrel - needs to be metabolized 
to an active metabolite by the hepatic CYP-enzymes. However, the metabolism of 
prasugrel is less dependent on some of the polymorphisms that restrict the bioavailability 
of the active clopidogrel metabolite. For this reason, in vivo generation of prasugrel
active metabolite is considerably more predictable. Prasugrel is, like clopidogrel, an 
irreversible inhibitor of the P2Y12 receptors, and peak plasma levels and half-lives are
similar. Ticagrelor does not need bio activation to achieve platelet inhibitory effect. This
drug directly, and in contrast to clopidogrel and prasugrel – reversibly - inhibits the 
platelet ADP P2Y12 receptor. Metabolism of ticagrelor also yields an active metabolite 
(mediated by the CYP-enzymes) that reaches about one third of the parent drug 
concentration. Maximum platelet inhibition after a 180 mg loading dose of ticagrelor or a 
60 mg loading dose of prasugrel is obtained within 2-4 hours, compared to 4-8 hours after 
administration of a 600 mg /300 mg loading dose of clopidogrel (the 600 mg loading 
dose of clopidogrel induces faster inhibition of platelet aggregation than the 300 mg 
loading dose) (33;48;50). Onset of action (measured as 50% platelet inhibition) is 
obtained after 2-4 ours for clopidogrel compared to 30 minutes for prasugrel and 
ticagrelor (33). Ticagrelor needs to be administered twice daily, while clopidogrel and 
prasugrel are given once daily. The roles of prasugrel and ticagrelor in future antiplatelet 
regimens are important and both have already been implemented in the Guidelines for 
treatment of ACS (33;34).
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11. CONCLUSIONS
Antiplatelet therapy with aspirin and clopidogrel has been a cornerstone in the treatment 
of CAD, but many patients still experience recurrent thrombotic events. There is 
according to literature an association between attenuated in-vitro platelet responses; 
labeled aspirin- and clopidogrel “resistance” or “non-responsiveness”, and adverse 
clinical outcomes. Since this seemed to be an important clinical problem, we wanted 
explore whether patients with pharmacodynamic aspirin and clopidogrel resistance could 
be identified by in vitro testing. As platelets can be activated through several pathways, 
our hypothesis was that receptor specific methods should be used in order to reveal 
whether aspirin and clopidogrel are unable to hit their pharmacological targets. 
Accordingly, we performed AA stimulated LTA to detect insufficient inhibition of the 
COX-1 enzyme (the pharmacological target for aspirin) and ADP stimulated LTA and 
MEA to assess inhibition of the ADP P2Y12-receptor (the pharmacological target for 
clopidogrel).
In our first study including 289 patients with stable CAD remitted for coronary 
angiography, we found that aspirin was capable of inhibiting COX-1 in all patients. 
Accordingly, pharmacodynamic non-responsiveness to aspirin must be rare. 
In the second study among 79 patients with stable CAD treated with PCI we found - as 
expected- considerable between-subject variability in ADP stimulated LTA aggregation 
both before and during clopidogrel therapy. These between-subject differences were 
significantly larger than the LTA measurement error, indicating that the differences 
reflect true biological variability. Moreover, there were significant within-subject 
variations in pre-treatment ADP aggregation over time, and although there were 
significant correlations between pre- and on-treatment aggregation values prediction of 
on-treatment ADP aggregation based on pre-treatment findings may be unreliable and 
should be done with caution.
In the third study based on 31 NSTEMI patients treated with aspirin and clopidogrel we 
found substantial between-subject variability in on-treatment ADP stimulated LTA 
aggregation – similar to our findings in our second study among stable CAD patients. 
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Findings based on MEA were similar. Moreover, between-subject variability in both
LTA and MEA aggregation was highly dependent on ADP concentration; i.e. higher 
ADP concentrations were associated with larger between-subject variability. 
Within-subject variability in platelet inhibition by clopidogrel over time determined by 
both LTA and MEA was moderate at all ADP concentrations, and the agreement between 
LTA and MEA was fairly good and stable over time in most patients. Accordingly, both 
LTA and MEA seemed suitable for detecting patients with high on-treatment platelet 
reactivity. Since we also found that LTA and MEA aggregation was similar in arterial 
and venous blood, our findings suggest that analyses based on venous samples reflect the 
situation in arterial blood, and that LTA may possibly be substituted by MEA in similar 
clinical settings.  
Our findings support the current opinion of many experts that failure to prevent recurrent 
thrombotic events despite antiplatelet therapy is not necessarily caused by 
pharmacodynamic drug resistance. The term “resistance” should be restricted to a drug’s 
failure to interact with its target. This may possibly be proper terminology as far as 
clopidogrel is concerned, but rarely in the case of aspirin. In lack of consensus on both 
methods of choice and definitions regarding inadequate clopidogrel responses, expert 
opinion still is that routine in vitro measurements of residual platelet reactivity in order to 
“tailor” antiplatelet medication is not recommended. 
52
Reference List
(1) Wright, JH. The origin and nature of blood platelets. Boston Medical and 
Surgical Journal 1906; 154: 643
(2) Bizzozero G. Su di un nuovo elemento morfologico del sangue del mammaiferi 
e sulla sua importanza nella trombosi e nele coagulazione. Osserv Gazz Clin 
1881; 17: 785-7
(3) Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of 
vascular endothelium: interactions between prostacyclin and nitric oxide. Br J 
Pharmacol 1987 Nov;92(3):639-46.
(4) Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood 
platelets showing no response to collagen fail to express surface glycoprotein Ia. 
Nature 1985 Dec 5;318(6045):470-2.
(5) Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet 
function. Nature 1975 Jun 26;255(5511):720-2.
(6) Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 
2001 Jul;86(1):189-97.
(7) Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient 
in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J 
Clin Invest 1989 Nov;84(5):1440-5.
(8) Kao KJ, Pizzo SV, McKee PA. Platelet receptors for human Factor VIII/von 
Willebrand protein: functional correlation of receptor occupancy and ristocetin-
induced platelet aggregation. Proc Natl Acad Sci U S A 1979 Oct;76(10):5317-
20.
(9) Schafer AI, Alexander RW, Handin RI. Inhibition of platelet function by 
organic nitrate vasodilators. Blood 1980 Apr;55(4):649-54.
(10) Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable 
coronary disease. N Engl J Med 1986 Oct 16;315(16):983-9.
(11) Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR. Arterial walls are 
protected against deposition of platelet thrombi by a substance (prostaglandin 
X) which they make from prostaglandin endoperoxides. Prostaglandins 1976 
Nov;12(5):685-713.
(12) Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of 
leukocyte adhesion. Proc Natl Acad Sci U S A 1991 Jun 1;88(11):4651-5.
(13) Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular 
relaxation is abnormal in the coronary microcirculation of atherosclerotic 
primates. Circulation 1990 May;81(5):1586-93.
53
(14) Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, et al. 
Evidence for two distinct G-protein-coupled ADP receptors mediating platelet 
activation. Thromb Haemost 1999 Jan;81(1):111-7.
(15) Offermanns S. The role of heterotrimeric G proteins in platelet activation. Biol 
Chem 2000 May;381(5-6):389-96.
(16) Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of
biologically active compounds derived from prostaglandin endoperoxides. Proc 
Natl Acad Sci U S A 1975 Aug;72(8):2994-8.
(17) Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic 
nucleotides. Biochem Pharmacol 2001 Nov 1;62(9):1153-61.
(18) Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008 
Aug 28;359(9):938-49.
(19) Miletich JP, Kane WH, Hofmann SL, Stanford N, Majerus PW. Deficiency of 
factor Xa-factor Va binding sites on the platelets of a patient with a bleeding 
disorder. Blood 1979 Nov;54(5):1015-22.
(20) Del MA, Evangelista V, Rajtar G, Chen ZM, Cerletti C, De GG. Platelet 
activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am 
J Physiol 1990 Mar;258(3 Pt 2):H870-H879.
(21) Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. 
Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by 
aspirin. Circulation 1997 Jan 7;95(1):63-8.
(22) Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and 
epinephrine. J Clin Invest 1979 Nov;64(5):1393-401.
(23) Bennett JS, Vilaire G, Burch JW. A role for prostaglandins and thromboxanes in 
the exposure of platelet fibrinogen receptors. J Clin Invest 1981 Oct;68(4):981-
7.
(24) Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert 
JM, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-
mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb 
Vasc Biol 1999 Aug;19(8):2007-11.
(25) Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA, Jr. 
Interleukin-1 activation of vascular endothelium. Effects on procoagulant 
activity and leukocyte adhesion. Am J Pathol 1985 Dec;121(3):394-403.
(26) Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of 
circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in 
a vascular injury model. Blood 1997 Feb 15;89(4):1270-8.
(27) Libby P. Coronary artery injury and the biology of atherosclerosis: 
inflammation, thrombosis, and stabilization. Am J Cardiol 2000 Oct 
19;86(8B):3J-8J.
54
(28) Schrijvers DM. De Meyer GR. Herman AG. Martinet W. Phagocytosis in 
arherosclerosis: Molecular mechanisms and implications for plaque progression 
and stability. Cardiovasc Res 2007;73(3):470-80.
(29)  Owens AP 3rd. Mackman N. Sources of tissue factor that contribute to    
thrombosis after rupture of an atherosclerotic plaque. Thromb Res. 2012;129 
Suppl 2:830-32.
(30) Szmitko PE.Wang CH. Weisel RD. de Almeida JR. Anderson TJ. Verma S. 
New Markers of Inflammation and Endothelial Cell Activation: Part I
Circulation 2003 Oct 21;108(16):1917-23
(31) Schönbeck U. Libby P. CD40 signaling and plaque instability. Circ Res 2001;89 
(12): 1092-1103.
(32) Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin 
synthetase by oral aspirin. J Clin Invest 1978 Feb;61(2):314-9.
(33) Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC 
Guidelines for the management of acute coronary syndromes in patients 
presenting without persistent ST-segment elevation: The Task Force for the 
management of acute coronary syndromes (ACS) in patients presenting without 
persistent ST-segment elevation of the European Society of Cardiology (ESC). 
Eur Heart J 2011 Dec;32(23):2999-3054.
(34) Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. ESC 
Guidelines for the management of acute myocardial infarction in patients 
presenting with ST-segment elevation: The Task Force on the management of 
ST-segment elevation acute myocardial infarction of the European Society of 
Cardiology (ESC). Eur Heart J 2012 Sep 11.
(35) Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human 
platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975 
Sep;56(3):624-32.
(36) Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic 
acetylation of platelet cyclooxygenase. N Engl J Med 1984 Nov 
8;311(19):1206-11.
(37) Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by 
aspirin. Proc Natl Acad Sci U S A 1975 Aug;72(8):3073-6.
(38) Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De SA, et al. Low 
dose aspirin and inhibition of thromboxane B2 production in healthy subjects. 
Thromb Res 1980 Feb 1;17(3-4):317-27.
(39) Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-
active drugs : the relationships among dose, effectiveness, and side effects. 
Chest 2001 Jan;119(1 Suppl):39S-63S.
55
(40) Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 
but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 
1991 Oct 17;325(16):1137-41.
(41) Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative 
antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985
Aug;60(4):635-42.
(42) Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of 
enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. 
Stroke 2006 Aug;37(8):2153-8.
(43) Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet 
thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 
1982 Jun;69(6):1366-72.
(44) Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994 May 
5;330(18):1287-94.
(45)  Savi P. Identification and biological activity of the active metabolite of 
clopidogrel. Thromb Haemost 2000; 84: 891-896.
(46) Plavix (prescribing information). Bridgewater, New Jersey: Bristol-Myers 
Squibb/Sanofi pharmaceuticals Partership, 2011.
(47) Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. 
Consensus and future directions on the definition of high on-treatment platelet 
reactivity to adenosine diphosphate. J Am Coll Cardiol 2010 Sep 
14;56(12):919-33.
(48) Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: consideration and 
management. J Interv Cardiol 2006 Oct;19(5):439-48.
(49) Bal Dit SC, Berge N, Boval B, Dubar M, Drouet L. Differential sensitivity and 
kinetics of response of different ex vivo tests monitoring functional variability 
of platelet response to clopidogrel. Thromb Haemost 2010 Sep;104(3):571-81.
(50) Oh EY, Abraham T, Saad N, Rapp JH, Vastey FL, Balmir E. A comprehensive 
comparative review of adenosine diphosphate receptor antagonists. Expert Opin 
Pharmacother 2012 Feb;13(2):175-91.
(51) Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug 
resistance. Arterioscler Thromb Vasc Biol 2004 Nov;24(11):1980-7.
(52) Järemo P. Individual variations of platelet inhibition after loading doses of 
clopidogrel. J Intern Med 2002; 252:233– 8..
(53) Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary 
stenting: response variability, drug resistance, and the effect of pretreatment 
platelet reactivity. Circulation 2003 Jun 17;107(23):2908-13.
56
(54) Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: 
pharmacological and disease-related mechanisms. Thrombosis 
2012;2012:376721.
(55) Cattaneo M. Resistance to anti-platelet agents. Thromb Res 2011 Feb;127 Suppl 
3:S61-S63.
(56) Born GV. Aggregation of blood platelets by adenosine diphosphate and its 
reversal. Nature 1962 Jun 9;194:927-9.
(57) Born GV, CROSS MJ. The aggregation of blood platelets. J Physiol 1963 
Aug;168:178-95.
(58) Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 
2009 Feb 2;103(3 Suppl):20A-6A.
(59) Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J 
Cardiol 2009 Feb 2;103(3 Suppl):27A-34A.
(60) Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular 
disease. Thromb Res 2003 Jun 15;110(5-6):281-6.
(61) Jackson SP. The growing complexity of platelet aggregation. Blood 2007 Jun 
15;109(12):5087-95.
(62) Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej 
E. Long-term aspirin and clopidogrel response evaluated by light transmission 
aggregometry, VerifyNow, and thrombelastography in patients undergoing 
percutaneous coronary intervention. Clin Chem 2010 May;56(5):839-47.
(63) Fitzgerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical 
and genetic factors. Pharmacol Ther 2011 May;130(2):213-25.
(64) Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et 
al. Impact of platelet reactivity after clopidogrel administration on drug-eluting 
stent thrombosis. J Am Coll Cardiol 2007 Jun 19;49(24):2312-7.
(65) Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, et al. Clopidogrel 
response: head-to-head comparison of different platelet assays to identify 
clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 
2010 Jan;103(1):39-45.
(66) Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et al. Low 
response to clopidogrel is associated with cardiovascular outcome after 
coronary stent implantation. Eur Heart J 2006 Oct;27(20):2420-5.
(67) Gori AM, Marcucci R, Paniccia R, Giusti B, Fedi S, Antonucci E, et al. 
Thrombotic events in high risk patients are predicted by evaluating different 
pathways of platelet function. Thromb Haemost 2008 Dec;100(6):1136-45.
(68) Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, et al. 
Assessment of platelet function on whole blood by multiple electrode 
57
aggregometry in high-risk patients with coronary artery disease receiving 
antiplatelet therapy. Am J Clin Pathol 2009 Jun;131(6):834-42.
(69) Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, et al. 
Comparison of methods for monitoring residual platelet reactivity after 
clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb 
Haemost 2010 Aug 2;104(2):287-92.
(70) Bal Dit SC, Berge N, Boval B, Hovsepian L, Drouet L. Functional variability of 
platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. 
Thromb Haemost 2009 Jan;101(1):116-22.
(71) Paniccia R, Antonucci E, Maggini N, Miranda M, Romano E, Gori AM, et al. 
Light transmittance aggregometry induced by different concentrations of 
adenosine diphosphate to monitor clopidogrel therapy: a methodological study. 
Ther Drug Monit 2011 Feb;33(1):94-8.
(72) Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents: 
towards personalized therapy? Nat Rev Cardiol 2011 Oct;8(10):560-71.
(73) Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler 
Thromb Vasc Biol 2008 Mar;28(3):s33-s38.
(74) von BN, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, et al. Assessment 
of platelet response to clopidogrel with multiple electrode aggregometry, the 
VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein 
flow cytometry. Blood Coagul Fibrinolysis 2010 Jan;21(1):46-52.
(75) Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, et al. 
Assessment of ADP-induced platelet aggregation with light transmission 
aggregometry and multiple electrode platelet aggregometry before and after 
clopidogrel treatment. Thromb Haemost 2008 Jan;99(1):121-6.
(76) Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, et 
al. A comparison of platelet function tests and thromboxane metabolites to 
evaluate aspirin response in healthy individuals and patients with coronary 
artery disease. Thromb Haemost 2010 Jun;103(6):1245-53.
(77) Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di RL, et al. 
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic 
patients under chronic aspirin treatment. Eur Heart J 2009 May;30(10):1279-86.
(78) Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet 
response to low-dose enteric-coated aspirin in patients with stable 
cardiovascular disease. J Am Coll Cardiol 2005 Oct 4;46(7):1258-63.
(79) Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, et al. The role 
of weight and enteric coating on aspirin response in cardiovascular patients. J 
Thromb Haemost 2010 Oct;8(10):2323-5.
58
(80) Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric 
coating on aspirin-induced inhibition of platelet aggregation in healthy 
volunteers. Am Heart J 2006 May;151(5):976-11.
(81) Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of 
platelet turnover on whole blood platelet aggregation in patients with coronary 
artery disease. J Thromb Haemost 2011 Jan;9(1):185-91.
(82) Stanford N, Roth GJ, Shen TY, Majerus PW. Lack of covalent modification of 
prostaglandin synthetase (cyclo-oxygenase) by indomethacin. Prostaglandins 
1977 Apr;13(4):669-75.
(83) Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand 
C. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. 
Thromb Res 2011 Jul;128(1):47-53.
(84) Serebruany V, Cherala G, Williams C, Surigin S, Booze C, Kuliczkowski W, et 
al. Association of platelet responsiveness with clopidogrel metabolism: role of 
compliance in the assessment of "resistance". Am Heart J 2009 Dec;158(6):925-
32.
(85) Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital 
and drug-induced defects. Blood 2010 Oct 21.
(86) Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et al. Genetic 
variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment 
with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a 
pharmacogenetic analysis. Lancet 2010 Oct 16;376(9749):1312-9.
(87) Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. 
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes 
of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a 
genetic substudy of the PLATO trial. Lancet 2010 Oct 16;376(9749):1320-8.
(88) Sibbing D, Taubert D, Schomig A, Kastrati A, von BN. Pharmacokinetics of 
clopidogrel in patients with stent thrombosis. J Thromb Haemost 2008 
Jul;6(7):1230-2.
(89) Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten CH, Hackeng CM, et al. 
Which platelet function test is suitable to monitor clopidogrel responsiveness? 
A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb 
Haemost 2010 Mar;8(3):482-8.
(90) Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll 
Cardiol 2011 Mar 15;57(11):1251-63.
(91) Frelinger AL, III, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A 
randomized, 2-period, crossover design study to assess the effects of 
dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-
state pharmacokinetics and pharmacodynamics of clopidogrel in healthy 
volunteers. J Am Coll Cardiol 2012 Apr 3;59(14):1304-11.
59
(92) Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, et 
al. Concomitant use of clopidogrel and proton pump inhibitors is not associated 
with major adverse cardiovascular events following coronary stent implantation. 
Aliment Pharmacol Ther 2012 Jan;35(1):165-74.
(93) Good CW, Steinhubl SR, Brennan DM, Lincoff AM, Topol EJ, Berger PB. Is 
there a clinically significant interaction between calcium channel antagonists 
and clopidogrel?: results from the Clopidogrel for the Reduction of Events 
During Observation (CREDO) trial. Circ Cardiovasc Interv 2012 Feb 1;5(1):77-
81.
(94) Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein 
IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation 
and effect of anticoagulant on antagonist potency. Implications for assay 
methodology and comparison of different antagonists. Circulation 1998 Oct 
20;98(16):1616-21.
(95) Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schomig A, et al. 
Stability of the high on-treatment platelet reactivity phenotype over time in 
clopidogrel-treated patients. Thromb Haemost 2011 Jan 3;105(1):107-12.
(96) Kafian S, Mobarrez F, Kalani M, Wallen H, Samad BA. Comparison of venous 
and arterial blood sampling for the assessment of platelet aggregation with 
whole blood impedance aggregometry. Scand J Clin Lab Invest 2011 Aug 28.
(97) Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. 
Increased risk in patients with high platelet aggregation receiving chronic 
clopidogrel therapy undergoing percutaneous coronary intervention: is the 
current antiplatelet therapy adequate? J Am Coll Cardiol 2007 Feb 
13;49(6):657-66.
(98) Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet 
reactivity in patients and recurrent events post-stenting: results of the 
PREPARE POST-STENTING Study. J Am Coll Cardiol 2005 Nov 
15;46(10):1820-6.
(99) Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. 
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results 
of the CREST Study. J Am Coll Cardiol 2005 Nov 15;46(10):1827-32.
(100) Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, et al. Clopidogrel 
response status assessed with Multiplate point-of-care analysis and the 
incidence and timing of stent thrombosis over six months following coronary 
stenting. Thromb Haemost 2010 Jan;103(1):151-9.
(101) Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman 
MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous 
coronary intervention with stenting: a systematic review and meta-analysis. Am
Heart J 2007 Aug;154(2):221-31.
(102) Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. 
Standard- vs high-dose clopidogrel based on platelet function testing after 
60
percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 
2011 Mar 16;305(11):1097-105.
(103) Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, et al. 
Functional impact of high clopidogrel maintenance dosing in patients 
undergoing elective percutaneous coronary interventions. Results of a 
randomized study. Thromb Haemost 2008 Jan;99(1):161-8.
61
62
          PAPER  I
          
          Øystein Meen,  Frank Brosstad, Hassan Khiabani 
Erik Gjertsen, May Ellen Lauritsen, Turid 
Margrethe Pedersen, Stine Bjørnsen, Nina Malja 
Schjelderup, Wivi Ameln, Ee Chye Ng, Marianne 
Wettergreen, Shazia Parveen Siddique, Gunnar 
Erikssen. 
          No case of COX-1 related aspirin resistance found 
in 289 patients with symptoms of stable CHD 
remitted for coronary angiography. 




          PAPER  II
          Øystein Meen, Frank Brosstad, Stine Bjørnsen, 
Turid Margrethe Pedersen and Gunnar Erikssen. 
          Variability in aggregometry response before and 
after initiation of clopidogrel therapy. 
          Scandinavian Journal of Clinical & Laboratory 
Investigation 2009; 69: 673-679.  

           PAPER  III
          Øystein Meen, Frank Brosstad, Knut Liestøl, 
Gabor Kunszt, Bjørn Bendz, Marianne 
Wettergreen, Nina Malja Schjelderup, Trine 
Andreassen, Gunnar Erikssen. 
          Sequential ADP-stimulated light transmission and 
multiple electrode aggregometry in patients 
taking aspirin and clopidogrel after non ST-
elevation myocardial infarction. 
         Scandinavian Journal of Clinical & Laboratory 
Investigation 2012; 72: 318-325.

